Profile data is unavailable for this security.
About the company
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
- Revenue in USD (TTM)435.83m
- Net income in USD-88.54m
- Incorporated2008
- Employees385.00
- LocationTravere Therapeutics Inc3611 Valley Centre Dr, Suite 300SAN DIEGO 92130United StatesUSA
- Phone+1 (760) 260-8600
- Fax+1 (302) 645-1280
- Websitehttps://travere.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mineralys Therapeutics Inc | 0.00 | -171.36m | 2.23bn | 51.00 | -- | 3.86 | -- | -- | -2.96 | -2.96 | 0.00 | 7.30 | 0.00 | -- | -- | 0.00 | -39.48 | -- | -42.14 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -147.31 | -- | -- | -- |
| Wave Life Sciences Ltd | 109.23m | -121.95m | 2.33bn | 287.00 | -- | 16.41 | -- | 21.33 | -0.7363 | -0.7363 | 0.6661 | 0.8262 | 0.3642 | -- | 21.85 | 380,592.30 | -40.66 | -48.01 | -71.05 | -88.09 | -- | -- | -111.64 | -205.56 | -- | -- | 0.00 | -- | -4.42 | 46.62 | -68.67 | -- | -24.87 | -- |
| Arcus Biosciences Inc | 240.00m | -341.00m | 2.46bn | 627.00 | -- | 4.92 | -- | 10.25 | -3.43 | -3.43 | 2.38 | 4.07 | 0.2156 | -- | 13.71 | 382,775.10 | -30.64 | -16.91 | -38.40 | -19.76 | -- | -- | -142.08 | -97.85 | -- | -- | 0.1835 | -- | 120.51 | 76.65 | 7.82 | -- | 25.53 | -- |
| Beam Therapeutics Inc | 55.70m | -414.64m | 2.51bn | 483.00 | -- | 2.59 | -- | 45.05 | -4.43 | -4.43 | 0.5936 | 9.53 | 0.0449 | -- | -- | 115,323.00 | -33.41 | -24.98 | -38.87 | -29.69 | -- | -- | -744.41 | -241.53 | -- | -- | 0.00 | -- | -83.18 | 412.30 | -184.28 | -- | -6.50 | -- |
| Adaptive Biotechnologies Corp | 252.75m | -79.61m | 2.51bn | 619.00 | -- | 12.29 | -- | 9.95 | -0.5381 | -0.5381 | 1.65 | 1.34 | 0.4818 | 6.50 | 5.90 | 408,326.30 | -15.17 | -21.92 | -18.12 | -24.85 | 71.84 | 64.77 | -31.49 | -119.25 | 3.26 | -55.47 | 0.3923 | -- | 5.10 | 16.04 | 29.19 | -- | -20.03 | -- |
| Spyre Therapeutics Inc | 0.00 | -148.97m | 2.56bn | 95.00 | -- | 6.66 | -- | -- | -2.55 | -2.55 | 0.00 | 7.53 | 0.00 | -- | -- | 0.00 | -32.19 | -75.44 | -36.25 | -85.33 | -- | -- | -- | -3,540.66 | -- | -- | 0.00 | -- | -100.00 | -- | 38.60 | -- | -- | -- |
| Travere Therapeutics Inc | 435.83m | -88.54m | 2.64bn | 385.00 | -- | 35.84 | -- | 6.05 | -1.08 | -1.08 | 4.80 | 0.8223 | 0.8357 | 1.74 | 8.06 | 1,132,018.00 | -16.98 | -41.64 | -24.67 | -51.97 | 97.63 | 95.90 | -20.32 | -175.36 | 2.71 | -- | 0.8089 | -- | 60.55 | 5.87 | 14.80 | -- | 45.42 | -- |
| Immunome Inc | 9.68m | -222.74m | 2.65bn | 118.00 | -- | 8.34 | -- | 273.58 | -2.95 | -2.95 | 0.122 | 2.88 | 0.0348 | -- | -- | 82,025.42 | -80.08 | -120.50 | -91.80 | -146.20 | -- | -- | -2,301.30 | -2,078.20 | -- | -- | 0.00 | -- | -35.50 | -- | -174.29 | -- | 196.63 | -- |
| Dyne Therapeutics Inc | 0.00 | -423.80m | 2.67bn | 240.00 | -- | 3.41 | -- | -- | -3.66 | -3.66 | 0.00 | 4.85 | 0.00 | -- | -- | 0.00 | -51.81 | -57.98 | -55.30 | -63.58 | -- | -- | -- | -- | -- | -- | 0.1254 | -- | -- | -- | -34.54 | -- | 7.60 | -- |
| Veracyte Inc | 495.14m | 30.32m | 2.76bn | 824.00 | 91.96 | 2.19 | 52.30 | 5.57 | 0.3791 | 0.3791 | 6.21 | 15.91 | 0.3747 | 7.66 | 10.25 | 600,899.30 | 2.29 | -4.19 | 2.43 | -4.43 | 68.53 | 66.82 | 6.12 | -13.70 | 5.94 | -- | 0.00 | -- | 23.46 | 29.93 | 132.44 | -- | 32.57 | -- |
| Viridian Therapeutics Inc | 70.79m | -301.97m | 2.78bn | 143.00 | -- | 7.64 | -- | 39.33 | -3.72 | -3.72 | 0.8716 | 6.12 | 0.105 | -- | 2.02 | 495,028.00 | -44.77 | -50.26 | -48.05 | -53.97 | -- | -- | -426.58 | -12,930.56 | -- | -- | 0.0399 | -- | -3.82 | -41.64 | -13.55 | -- | 43.49 | -- |
| Ideaya Biosciences Inc | 214.83m | -160.74m | 2.79bn | 131.00 | -- | 2.55 | -- | 12.96 | -1.85 | -1.85 | 2.43 | 12.46 | 0.1772 | -- | -- | 1,639,954.00 | -13.26 | -22.71 | -13.86 | -24.48 | -- | -- | -74.82 | -411.78 | -- | -- | 0.00 | -- | -70.07 | -- | -142.98 | -- | 23.31 | -- |
| Vera Therapeutics Inc | 0.00 | -251.94m | 2.87bn | 224.00 | -- | 6.56 | -- | -- | -3.98 | -3.98 | 0.00 | 6.24 | 0.00 | -- | -- | 0.00 | -56.87 | -54.55 | -61.62 | -60.06 | -- | -- | -- | -- | -- | -- | 0.1576 | -- | -- | -- | -58.50 | -- | 50.71 | -- |
| Edgewise Therapeutics Inc | 0.00 | -157.24m | 2.88bn | 136.00 | -- | 5.15 | -- | -- | -1.58 | -1.58 | 0.00 | 5.28 | 0.00 | -- | -- | 0.00 | -28.73 | -26.21 | -29.83 | -27.42 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -33.60 | -- | 48.78 | -- |
| Disc Medicine Inc | 0.00 | -181.11m | 2.96bn | 84.00 | -- | 4.78 | -- | -- | -5.35 | -5.35 | 0.00 | 16.38 | 0.00 | -- | -- | 0.00 | -32.18 | -- | -33.75 | -- | -- | -- | -- | -- | -- | -- | 0.0481 | -- | -- | -- | -43.08 | -- | -- | -- |
| Viking Therapeutics Inc | 0.00 | -237.39m | 2.97bn | 50.00 | -- | 4.15 | -- | -- | -2.12 | -2.12 | 0.00 | 6.34 | 0.00 | -- | -- | 0.00 | -28.31 | -22.44 | -29.21 | -23.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -28.02 | -- | -- | -- |
Data as of Feb 06 2026. Currency figures normalised to Travere Therapeutics Inc's reporting currency: US Dollar USD
56.68%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Janus Henderson Investors US LLCas of 30 Sep 2025 | 10.39m | 11.61% |
| Armistice Capital LLCas of 30 Sep 2025 | 6.72m | 7.52% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 6.67m | 7.45% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 5.59m | 6.25% |
| Nomura Investment Management Business Trustas of 30 Sep 2025 | 4.98m | 5.57% |
| Perceptive Advisors LLCas of 06 Oct 2025 | 4.90m | 5.47% |
| Adage Capital Management LPas of 30 Sep 2025 | 3.55m | 3.97% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 3.22m | 3.60% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 2.52m | 2.82% |
| Rock Springs Capital Management LPas of 30 Sep 2025 | 2.16m | 2.42% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
